Subscribe To
ATNX / Athenex (ATNX) Upgraded to Buy: Here's Why
ATNX News
By InvestorPlace
May 15, 2023
Why Is Athenex (ATNX) Stock Down 54% Today?
Athenex (NASDAQ: ATNX ) stock is falling on Monday after the company announced an agreement with lenders to pursue an expedited sales process. Accordi more_horizontal
By Zacks Investment Research
March 23, 2023
Athenex (ATNX) Upgraded to Buy: Here's Why
Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st more_horizontal
By InvestorPlace
December 20, 2022
Why Is Athenex (ATNX) Stock Up 44% Today?
Athenex (NASDAQ: ATNX ) stock is rocketing higher on Tuesday thanks to positive results from a high-risk early-stage breast cancer clinical trial. The more_horizontal
By Seeking Alpha
November 6, 2022
Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call Transcript
Athenex, Inc. (NASDAQ:ATNX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Tim McCarthy - MD, Investor Relations J more_horizontal
By Seeking Alpha
July 28, 2022
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2022 Results - Earnings Call Transcript
Athenex, Inc. (NASDAQ:ATNX ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Caileigh Dougherty - Director, Investor Re more_horizontal
By GlobeNewsWire
May 2, 2022
Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for
BUFFALO, N.Y., May 02, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, an more_horizontal
By GlobeNewsWire
May 2, 2022
Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for
BUFFALO, N.Y., May 02, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, an more_horizontal
By Seeking Alpha
March 16, 2022
Athenex, Inc. (ATNX) CEO Johnson Lau on Q4 2021 Results - Earnings Call Transcript
Athenex, Inc. (ATNX) CEO Johnson Lau on Q4 2021 Results - Earnings Call Transcript more_horizontal
